A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Esaxerenone (Primary) ; Eplerenone
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ESAX-HTN
- Sponsors Daiichi Sankyo Company
- 15 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2016 Status changed from not yet recruiting to recruiting.
- 20 Aug 2016 New trial record